# Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch

> **NCT02697045** · PHASE4 · COMPLETED · sponsor: **Abdi İbrahim Otsuka** · enrollment: 23 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole 400mg LAI

## Key facts

- **NCT ID:** NCT02697045
- **Lead sponsor:** Abdi İbrahim Otsuka
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-04
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-03-31
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02697045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02697045, "Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02697045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*